Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 ( in treating patients of non-small cell lung cancer at peri-operational stage

详细信息    查看全文

• 作者：Qing-cong Du (1)
  Kui-zhong Yang (1)
  Xue-fei Sun (1)
  
• 关键词：non ; small cell lung cancer ; peri ; operational stage ; immune function ; Danggui Buxue Decoction No.1 ; immunotherapy
• 刊名：Chinese Journal of Integrative Medicine
• 出版年：2009
• 出版时间：June 2009
• 年：2009
• 卷：15
• 期：3
• 页码：184-188
• 全文大小：217KB
• 参考文献：1. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007; 57:365-72. CrossRef
  2. Abiko T, Kawamura M, Izumi Y, Oyama T, Saito Y, Kobayashi K. Prediction of anti-tumour effect of thermochemotherapy with / in vitro thermochemosensitivity testing for non-small cell lung cancer. Int J Hyperthermia 2007;23:267-75. CrossRef
  3. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Reviews 2006;214: 229-38. CrossRef
  4. Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor α in advanced non-small cell lung Cancer. Am J Clin Oncol 1995;18:47-1. CrossRef
  5. Oum Ji-Hyun, Han Juhyun, Myung Heejoon, Hleb Marija, Sharm urendra, Park Jungchan. Molecular mechanism of NFAT family proteins for differential regulation of the IL-2 and TNF-α promoters. Molecules Cells 2002;13: 77-4.
  6. Van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Splinter TA. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: CYFRA21-1. Br J Cancer 1994;69: 525-28.
  7. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeration subunit 19 measured by CYFRA21-1. Immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-6.
  8. Yuan SD, Ding JR, Wang SX, Cui J, Zhou JQ, Lou ZL, et al. The monitoring function of CYFRA21-1 in the treatment of non-small-cell lung cancer. Chin J Mod Med (Chin) 1997;7:9-2.
  
• 作者单位：Qing-cong Du (1)
  Kui-zhong Yang (1)
  Xue-fei Sun (1)
  
  1. The Fourteen Area, Wujing Shandong Zongdui Hospital, Jinan, 250014, China
  

文摘

Objective To observe the therapeutic efficacy of Danggui Buxue Decoction No.1 ( DB1) in treating patients of non-small cell lung cancer (NSCLC) at the peri-operational stage and its impact on the patients-immune function. Methods Eighty-two NSCLC patients were randomly assigned to two groups equally, the control group and the test group, they were given conventional treatment, while to the test group, DB1 were given additionally. The observation was conducted by testing the changes of T-lymphocyte subsets, natural killer (NK) cell activity, serum levels of immunoglobulin (IgA, IgM, IgG), interleukin-2 (IL-2), tumor necrosis factor α (TNF-α), cytokeratin fragment 19 (CYFRA21-1) and carcinoembryonic antigen (CEA) in NSCLC patients before and after administration of DB1, and analyzing the patients-general condition. Results The level of CD3+, CD4+, the ratio of CD4 and CD8+, IgA, IgM, IgG and IL-2 decreased in patients with NSCLC on day 1 after operation, and the level of CD8 and TNF-α increased compared to pre-operation. While the levels of CD3+, CD4+, CD4 /CD8+, NK cell activity, serum IgA, IgM, IgG, IL-2 began to elevate, CD8 and TNF-α levels began to decline in patients administered with DB1 on day 3 after the operation, earlier than patients who did not use the decoction. The level of CYFRA21-1 and CEA, was immediately decreased after operation in both groups. Conclusions Applying DB1 to NSCLC patients at an early post-operational stage could alleviate the impairment and accelerate the recovery of immune function of patients to enhance their immunity. DB1 also shows an anti-tumor action to a certain degree.